Endometrial cancer risk factors by 2 main histologic subtypes

American Journal of Epidemiology

Volumn 177, Issue 2, 2013, Pages 142-151

  Yang, Hannah P ^a   Wentzensen, Nicolas ^a   Trabert, Britton ^a   Gierach, Gretchen L ^a   Felix, Ashley S ^a   Gunter, Marc J ^b   Hollenbeck, Albert ^c   Park, Yikyung ^d   Sherman, Mark E ^a   Brinton, Louise A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c AARP   (United States)

^d NONE   (United States)

Author keywords

endometrial cancer; endometrioid; histology; nonendometrioid; prospective study

Indexed keywords

CANCER; COHORT ANALYSIS; HEALTH RISK; HORMONE; REGRESSION ANALYSIS; RISK FACTOR; TUMOR; WOMENS HEALTH;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOLOGY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SELF REPORT; UNITED STATES;

EID: 84872225562     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws200     Document Type: Article

References (52)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-236.
2. Lu KH. Management of early-stage endometrial cancer. Semin Oncol. 2009;36(2):137-144.
3. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control. 2009;16(1):46-52.
4. Lim D, Oliva E. Nonendometrioid endometrial carcinomas. Semin Diagn Pathol. 2010;27(4):241-260.
5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-17.
6. Emons G, Fleckenstein G, Hinney B, et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer. 2000;7(4):227-242.
7. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecularbased classification. Virchows Arch. 2004;444(3):213-223.
8. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13(3):295-308.
9. Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol. 1997;10(10):963-968.
10. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29(6):551-558.
11. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999;74(3):385-394.
12. Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851-1856.
13. Schatzkin A, Subar AF, Thompson FE, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol. 2001;154(12):1119-1125.
14. Michaud DS, Midthune D, Hermansen S, et al. Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Registry Manag. 2005;32(2):70-75.
15. ICD-O-3 SEER site/histology validation list. Rockville, MD: SEER Program Quality Control Section; 2007. (http://seer. cancer.gov/icd-o-3/sitetype.icdo3. d08152007.pdf). (Accessed December 15, 2011).
16. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51(2):524-532.
17. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Related Cancer. 2008;15(2):485-497.
18. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol. 2008;630:148-165.
19. Henderson BE, Feigelson HS., Hormonal carcinogenesis. Carcinogenesis. 2000;21(3):427-433.
20. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1531-1543.
21. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004;108(3):425-432.
22. Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol. 2010;172(12):1394- 1403.
23. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134. (doi:10.1136/bmj.39367.495995.AE).
24. Bjorge T, Engeland A, Tretli S, et al. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer. 2007;120(2):378-383.
25. McCullough ML, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev. 2008; 17(1):73-79.
26. Mauland KK, Trovik J, Wik E, et al. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer. 2011; 104(6):921-926.
27. Mahabir S, Baer DJ, Johnson LL, et al. Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2006; 15(12):2502-2507.
28. Baglietto L, English DR, Hopper JL, et al. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat. 2009;115(1):171-179.
29. Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010;28(1):81-90.
30. Beral V, Bull D, Reeves G. Endometrial cancer and hormonereplacement therapy in the Million Women Study. Lancet. 2005;365(9470):1543-1551.
31. Canchola AJ, Chang ET, Bernstein L, et al. Body size and the risk of endometrial cancer by hormone therapy use in postmenopausal women in the California Teachers Study cohort. Cancer Causes Control. 2010;21(9):1407-1416.
32. Chang SC, Lacey JV Jr, Brinton LA, et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP Diet and Health Study. Cancer Epidemiol Biomarkers Prev. 2007;16(4):723-730.
33. Friedenreich C, Cust A, Lahmann PH, et al. Anthropometric factors and risk of endometrial cancer: the European Prospective Investigation Into Cancer and Nutrition. Cancer Causes Control. 2007;18(4):399-413.
34. Matthews RP, Hutchinson-Colas J, Maiman M, et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol. 1997;65(2):206-212.
35. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98(1):176-186.
36. Wright JD, Fiorelli J, Schiff PB, et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer. 2009;115(6):1276-1285.
37. Clifford SL, Kaminetsky CP, Cirisano FD, et al. Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol. 1997; 176(6):S229-S232.
38. Santin AD, Bellone S, Siegel ER, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192(3):813-818.
39. Kelsey JL, LiVolsi VA, Holford TR, et al. A case-control study of cancer of the endometrium. Am J Epidemiol. 1982;116(2):333-342.
40. Parazzini F, La Vecchia C, Negri E, et al. Family history of breast, ovarian and endometrial cancer and risk of breast cancer. Int J Epidemiol. 1993;22(4):614-618.
41. Kazerouni N, Schairer C, Friedman HB, et al. Family history of breast cancer as a determinant of the risk of developing endometrial cancer: a nationwide cohort study. J Med Genet. 2002;39(11):826-832.
42. Lucenteforte E, Talamini R, Montella M, et al. Family history of cancer and the risk of endometrial cancer. Eur J Cancer Prev. 2009;18(2):95-99.
43. Lavie O, Ben-Arie A, Segev Y, et al. BRCA germline mutations in women with uterine serous carcinoma-still a debate. Int J Gynecol Cancer. 2010;20(9): 1531-1534.
44. Gehrig PA, Bae-Jump VL, Boggess JF, et al. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol. 2004;94(1):208-211.
45. Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol. 2012;124(1):15-20.
46. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000;77(1): 55-65.
47. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004;35(6):649-662.
48. Ioffe OB. Recent developments and selected diagnostic problems in carcinomas of the endometrium. Am J Clin Pathol. 2005;124(suppl):S42-S51.
49. Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 2008;108(3-5): 221-229.
50. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int. 2010;2010: Article ID 162363. (doi:10.1155/2010/162363).
51. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642-646.
52. Soslow RA, Bissonnette JP, Wilton A, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol. 2007;31(7):979-987.